Managing the path to an IPO

Macro concerns continue to weigh on the broader biotech sector, but a growing number of maturing private biotech companies are gearing up for an IPO next year.

With investors still feeling stung from the poor performance of the 2020-21 biotech IPO frenzy, companies will have to meet more stringent criteria to attract investor attention, including de-risked assets in large markets led by experienced management teams that have reasonable expectations when it comes to valuation. ...